This discussion aims to raise awareness for the importance of molecular assessments and biomarker-guided treatment selection to help healthcare professionals make better informed and individualized treatment decisions for patients with NSCLC and other cancers. Data have shown that genomic-matched treatments and clinical trials, are often less toxic, more efficacious, and less expensive than traditional cytotoxic chemotherapy and have the potential to achieve better patient quality of life. It is important for healthcare professionals to understand the process, and rationale, behind the development of targeted therapies as they continue to lead to the integration of genomic-guided therapies in clinical settings. Available in English.
- Provider:Postgraduate Institute for Medicine
- Activity Link: https://targeted-therapies-lung-cancer.ime.springerhealthcare.com/podcast/?podcast=1
- Start Date: 2024-05-20 05:00:00
- End Date: 2024-05-20 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.25 hours
- Commercial Support: Source: illumina - Amount: 63838.0 - Is Kind Support: False Source: Roche (Any division) - Amount: 12500.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest